{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-25-000074","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.281176+00:00","generated_at":"2026-05-17T05:06:20.556493+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CAMP4 initiates GLP toxicology studies for CMP-SYNGAP-01; Phase 1/2 target H2 2026","bullets":["Initiated GLP toxicology studies for CMP-SYNGAP-01, a regulatory RNA-targeting therapeutic for SYNGAP1-related disorders.","Positive preclinical data: restored SYNGAP1 protein in mouse model, increased protein in brain regions of non-human primates.","Planned CTA submission could enable first-in-human Phase 1/2 trial as early as H2 2026.","No FDA-approved disease-modifying therapies exist for SYNGAP1-related disorders; current treatment limited to supportive care."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-25-000074","json":"https://secwatch.observer/filing/0001736730-25-000074.json","markdown":"https://secwatch.observer/filing/0001736730-25-000074.md","text":"https://secwatch.observer/filing/0001736730-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000074/0001736730-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000074/camp-20251001.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:06:20.556493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}